Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) announced a live conference call on May 3, 2022, at 8:30 a.m. ET to discuss its first quarter 2022 financial results and corporate updates. Investors can dial in at 844-200-6205 (domestic) or 929-526-1599 (international) with conference ID 694684. The call will also be available via webcast on their website, with an archived version accessible for 30 days. Blueprint Medicines focuses on developing targeted therapies for cancer and blood disorders.

Positive

• Announcement of a live conference call to discuss Q1 2022 financial results indicates transparency and investor engagement.

Negative

• None.

CAMBRIDGE, Mass., April 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 3, 2022 to report its first quarter 2022 financial results and provide a corporate update.

To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international), and refer to conference ID 694684. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-first-quarter-2022-financial-results-on-tuesday-may-3-2022-301532566.html

SOURCE Blueprint Medicines Corporation

FAQ

When is Blueprint Medicines' first quarter 2022 earnings call?

The earnings call is scheduled for May 3, 2022, at 8:30 a.m. ET.

How can I access the Blueprint Medicines earnings call?

You can access the call by dialing 844-200-6205 (domestic) or 929-526-1599 (international) with conference ID 694684, or via the webcast on their website.

What is the focus of Blueprint Medicines Corporation?

Blueprint Medicines focuses on developing precision therapies for cancer and blood disorders.

Where can I find the archived earnings call?

The archived webcast will be available on Blueprint Medicines' website approximately two hours after the call.